147 related articles for article (PubMed ID: 37234342)
1. Design, synthesis, antitumor evaluation, and molecular docking of novel pyrrolo[2,3-d]pyrimidine as multi-kinase inhibitors.
Alanazi AS; Mirgany TO; Alsaif NA; Alsfouk AA; Alanazi MM
Saudi Pharm J; 2023 Jun; 31(6):989-997. PubMed ID: 37234342
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
3. Novel 7-Deazapurine Incorporating Isatin Hybrid Compounds as Protein Kinase Inhibitors: Design, Synthesis, In Silico Studies, and Antiproliferative Evaluation.
Alanazi MM; Alanazi AS
Molecules; 2023 Aug; 28(15):. PubMed ID: 37570839
[TBL] [Abstract][Full Text] [Related]
4. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
6. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative Activity, Multikinase Inhibition, Apoptosis- Inducing Effects and Molecular Docking of Novel Isatin-Purine Hybrids.
Alanazi AS; Mirgany TO; Alsfouk AA; Alsaif NA; Alanazi MM
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984611
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
12. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and molecular docking of new fused 1
Belal A; Abdel Gawad NM; Mehany ABM; Abourehab MAS; Elkady H; Al-Karmalawy AA; Ismael AS
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1884-1902. PubMed ID: 35801486
[TBL] [Abstract][Full Text] [Related]
15. Discovery of New Pyrrolo[2,3-
Alotaibi AA; Alanazi MM; Rahman AFMM
Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765132
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
[TBL] [Abstract][Full Text] [Related]
17. Design and Synthesis of New Thiophene/Thieno[2,3-
Elmongy EI; Attallah NGM; Altwaijry N; AlKahtani MM; Henidi HA
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011354
[TBL] [Abstract][Full Text] [Related]
18. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
[TBL] [Abstract][Full Text] [Related]
19. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy.
Ibrahim TS; Hawwas MM; Taher ES; Alhakamy NA; Alfaleh MA; Elagawany M; Elgendy B; Zayed GM; Mohamed MFA; Abdel-Samii ZK; Elshaier YAMM
Bioorg Chem; 2020 Dec; 105():104352. PubMed ID: 33080494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]